Biopharmaceutical company Regulus Therapeutics Inc (NASDAQ:RGLS) has announced the appointment of Timothy Wright, MD, as chief research & development officer.
The company, which specialises in the discovery and development of innovative medicines targeting microRNAs (ribonucleic acida), said Dr Wright would report to Paul Grint, MD, president and chief executive officer of Regulus.
Dr. Wright will oversee Regulus’s research, drug discovery, clinical development, and regulatory affairs functions.
“Tim brings over 30 years of academic and industry experience that includes leading worldwide clinical development programs,” said Grint.
“His expertise in translational research will enable us to significantly advance and develop our pipeline. With three clinical-stage compounds, a fourth clinical candidate to be nominated by year-end, and multiple promising compounds in our pipeline, Tim joins us at an exciting time in the evolution of the company.”
Shares in Regulus rose 8.6% to US$3.52 on the news.
Story by ProactiveInvestors